GH: יחס חוב לטווח ארוך להון עצמי Guardant Corp

Guardant Health, Inc. (GH) is a leader in FDA-approved non-invasive liquid biopsy for oncology. This chart on GURU.Markets reflects the asset's price action, where the current value is 0.00. The business generates revenue through high-tech tests for therapy selection. The company is currently scaling its early detection systems, expanding insurance coverage and securing necessary regulatory approvals in the US.

This ratio measures the proportion of long-term liabilities within the equity structure, determining the issuer's degree of financial autonomy and credit load risks. For Guardant Health, Inc. (GH), whose oncology diagnostic services are independent of economic cycles, the ratio of long-term loans to equity confirms the company's ability to scale its business without compromising stability, driven by the inelastic demand for medical tests.